フルルビプロフェン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H301：飲み込むと有毒

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P405：施錠して保管すること。

  P501：内容物/容器を．．．に廃棄すること。

フルルビプロフェン 価格

MSDS Information

• Flurbiprofen

フルルビプロフェン 化学特性,用途語,生産方法

• 外観

  白色～うすい黄色, 結晶～粉末

• 溶解性

  メタノールに可溶

• 用途

  イブプロフェン類縁体の非ス テロイド系抗炎症剤です。フルルビプロフェ ンはシクロオキシゲナーゼ（COX）を阻害す ることで、発熱・炎症作用を抑制します。

• 用途

  プロピオン酸系化合物です。 シクロオキシゲナーゼ（COX）を阻害し、プ ロスタグランジン生合成抑制作用を示します。

• 用途

  フルルビプロフェンとは、で表されるフェニルアルカン酸誘導体の1種である。プロパン酸系の非ステロイド性抗炎症薬として、関節炎による痛みの緩和などに用いられる。

• 効能

  鎮痛薬, 抗炎症薬, シクロオキシゲナーゼ阻害薬

• 商品名

  アドフィード (リードケミカル); ゼポラス (三笠製薬); ゼポラス (三笠製薬); フルルバン (大協薬品工業); フルルバン (大協薬品工業); フロベン (科研製薬); ヤクバン (トクホン)

• 説明

  Flurbiprofen synthesis was originally reported in 1974. During a study of the pharmacological properties of a large number of substituted phenylalkanoic acids, including ibuprofen and ibufenac, the most potent were found to be substituted 2-(4-biphenyl)propionic acids. Further toxicological and pharmacological studies indicated that flurbiprofen possessed the most favorable therapeutic profile, so it was selected for further clinical development. It was not marketed until 1987, when it was introduced as the sodium salt as Ocufen, the first topical NSAID indicated for ophthalmic use in the United States. The indication for Ocufen is the same as that for Profenal—that is, to inhibit intraoperative miosis induced by prostaglandins in cataract surgery.

• 化学的特性

  White to Off-White Crystalline Solid

• 使用

  An anti-inflammatory used as an analgesic.

• 適応症

  Flurbiprofen (Ansaid) is indicated for the treatment of rheumatoid arthritis and osteoarthritis. Its half-life, longer than that of many of the NSAIDs, allows for twice daily dosing.The most common adverse effects of flurbiprofen are similar to those of the other acidic NSAIDs. Flurbiprofen inhibits both COX isoforms about equally.

• 一般的な説明

  Flurbiprofen (Ansaid, Ocufen, Froben), is another drug inthis class indicated for both acute and long-term managementof RA and OA but with a more complex mechanism ofaction. Unlike the other drugs in this class, it does not undergochiral inversion (i.e., the conversion of the “inactive”[R]-enantiomer to the active, [S]-enantiomer). Similar to aspirinand other salicylates, both flurbiprofen enantiomersblock COX-2 induction as well as inhibiting the nuclearfactor-κB-mediated polymorphonuclear leukocyte apoptosissignaling; therefore, both enantiomers are believed to contributeequally to its overall anti-inflammatory action.
  (R)-flurbiprofen is actually a strong clinical candidate forthe treatment of Alzheimer disease, because it has beenshown to reduce Aβ42 production by human cells.

• 生物活性

  Potent inhibitor of cyclooxygenase (IC 50 values are 0.1 and 0.4 μ M for inhibition of human COX-1 and COX-2 respectively). Analgesic, anti-inflammatory and antipyretic in vivo . Inhibits tumor cell growth in vitro and in vivo . Also inhibits fibroblast proliferation in vitro .

• 薬物動態学

  Flurbiprofen is well absorbed after oral administration, with peak plasma levels being attained within 1.5 hours. Food alters the rate of absorption but not the extent of its bioavailability. It is extensively bound to plasma proteins (99%).and has a plasma half-life of 2 to 4 hours. Metabolism is extensive, with 60 to 70% of flurbiprofen and its metabolites being excreted as sulfate and glucuronide conjugates. Flurbiprofen shows some interesting metabolic patterns, with 40 to 47% as the 4′-hydroxy metabolite, 5% as the 3′,4′-dihydroxy metabolite, 20 to 30% as the 3′-hydroxy- 4′-methoxy metabolite, and the remaining 20 to 25% of the drug being excreted unchanged. None of these metabolites demonstrates significant anti-inflammatory activity.

• 臨床応用

  Flurbiprofen is indicated as an oral formulation for the acute or long-term treatment of rheumatoid arthritis and osteoarthritis and as an ophthalmic solution for the inhibition of intraoperative miosis.

フルルビプロフェン 上流と下流の製品情報

フルルビプロフェン 生産企業

Global(547)Suppliers

フルルビプロフェン スペクトルデータ(¹HNMR、¹³CNMR、IR1、IR2、MS)

5104-49-4, フルルビプロフェン キーワード